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Original Research

Operative Versus Nonoperative Treatment
of Acute Achilles Tendon Ruptures
A Pilot Economic Decision Analysis
Alvin W. Su,*† MD, PhD, Ljiljana Bogunovic,* MD, Jeffrey Johnson,* MD, Sandra Klein,* MD,
Matthew J. Matava,* MD, Jeremy McCormick,* MD, Matthew V. Smith,* MD, MS,
Rick W. Wright,* MD, and Robert H. Brophy,*‡ MD
Investigation performed at the Department of Orthopaedic Surgery,
Washington University in St Louis, St Louis, Missouri, USA
Background: The operative treatment of Achilles tendon ruptures has been associated with lower rerupture rates and better
function but also a risk of surgery-related complications compared with nonoperative treatment, which may provide improved
outcomes with accelerated rehabilitation protocols. However, economic decision analyses integrating the updated costs of both
treatment options are limited in the literature.
Purpose: To compare the cost-effectiveness of operative and nonoperative treatment of acute Achilles tendon tears.
Study Design: Economic and decision analysis; Level of evidence, 2.
Methods: An economic decision model was built to assess the cost-utility ratio (CUR) of open primary repair versus nonoperative
treatment for acute Achilles tendon ruptures, based on direct costs from the practices of sports medicine and foot and ankle
surgeons at a single tertiary academic center, with published outcome probabilities and patient utility data. Multiway sensitivity
analyses were performed to reflect the range of data.
Results: Nonoperative treatment was more cost-effective in the average scenario (nonoperative CUR, US$520; operative CUR,
US$1995), but crossover occurred during the sensitivity analysis (nonoperative CUR range, US$224-US$2079; operative CUR
range, US$789-US$8380). Operative treatment cost an extra average marginal CUR of US$1475 compared with nonoperative
treatment, assuming uneventful healing in both treatment arms. The sensitivity analysis demonstrated a decreased marginal CUR
of operative treatment when the outcome utility was maximized, and rerupture rates were minimized compared with nonoperative
treatment.
Conclusion: Nonoperative treatment was more cost-effective in average scenarios. Crossover indicated that open primary repair
would be favorable for maximized outcome utility, such as that for young athletes or heavy laborers. The treatment decision for
acute Achilles tendon ruptures should be individualized. These pilot results provide inferences for further longitudinal analyses
incorporating future clinical evidence.
Keywords: Achilles tendon; decision analysis; cost-effectiveness

The optimal treatment approach for acute Achilles tendon
ruptures is evolving and controversial.9,22 Common measures to assess the effectiveness of treatment include rerupture rate, posttreatment complications, subjective and
objective outcome measurements, and time to return to
play or work.7,9,19,21,29 Open surgical repair has traditionally been considered the gold standard for active patients.6
Nonoperative treatment has demonstrated comparable
rerupture rates and similar functional recovery when

incorporating accelerated functional rehabilitation protocols that allow earlier weightbearing and more aggressive
progression in ankle range of motion.1,2,19,23,29,30
Quantitative decision analyses can be used to assess
medical decision making through a decision tree that integrates variables such as the outcome utility, costs, and
probabilities of events for each treatment arm. Expected
utility value analyses can predict the utility values for each
arm as the proxy for its effectiveness, which can serve as
the basis for cost-effectiveness analyses to assess the economic impact of treatment. There are limited decision analysis reports in the current literature for the management of
acute Achilles tendon ruptures. A recent study slightly
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Figure 1. The (A) decision tree and (B) foldback analysis for the clinical decision scenario of an acute Achilles tendon rupture.
c: decision node; : chance node; : terminal node. The probability and utility values shown at the terminal nodes were average
values, with the ultimate utility values from the foldback analysis shown at the chance nodes, together with the average and range
of direct costs.
supported the cost-effectiveness of surgical treatment
according to data prospectively collected at a single institution in Sweden,27 while another study based on a claims
database in the United States (US) showed a lower cost of
nonoperative treatment from the payer’s perspective.20 The
most recent expected value decision analysis based on data
in the US, published in 2002, concluded that open surgical
repair may be the preferred treatment option because of its
superior patient outcome utility value.11
In light of new evidence comparing operative and nonoperative treatment and the relative paucity of studies on the
cost-effectiveness of treating Achilles tendon ruptures, the
purpose of the present study was to compare the costeffectiveness of open surgical repair and nonoperative
treatment of acute Achilles tendon ruptures.

analysis,11 and outcome probabilities from a recent level 1
systematic review.28 In short, utility values serve as a surrogate for patient-reported satisfaction with the treatment
results. Probabilities reflect how likely each treatment
result will ensue.
The analytical model was built on a decision tree. The
initial binary decision node led to 2 arms of treatment,
represented by 2 chance nodes: (1) operative (OP; open surgical repair) and (2) nonoperative (NOP). Subsequent terminal events in each treatment arm were represented by 5
terminal nodes—(1) well-being, (2) rerupture of the Achilles tendon, (3) major complication, (4) moderate complication, and (5) minor complication—similar to the algorithm
as previously described11 (Figure 1A).

Definition of Events and Variables
METHODS
Study Design
This study was an economic decision analysis with multiway sensitivity analyses based on actual direct cost data,
expected utility values from a previously published decision

The 5 terminal events were defined as previously described
in a high-quality systematic review 28 and a decision
analysis.11 Major complications were defined as one of the
following: deep vein thrombosis or pulmonary embolism
either after OP or NOP treatment or a deep infection that
required a surgical intervention. Moderate complications
were defined as one of the following: a superficial infection

‡
Address correspondence to Robert H. Brophy, MD, Department of Orthopaedic Surgery, Washington University in St Louis, 14532 South Outer Forty
Drive, Chesterfield, MO 63017, USA (email: brophyrh@wustl.edu).
*Department of Orthopaedic Surgery, Washington University in St Louis, St Louis, Missouri, USA.
†
Nemours Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA.
Final revision submitted October 27, 2019; accepted December 17, 2019.
One or more of the authors has declared the following potential conflict of interest or source of funding: L.B. has received educational support from Elite
Orthopaedics and hospitality payments from Arthrex and Smith & Nephew. J.J. has received educational support from Arthrex, consulting fees from Tornier
and Wright Medical, speaking fees from Arthrex, royalties from Tornier and Wright Medical, and hospitality payments from Stryker. M.J.M. has received
educational support from Arthrex, Breg, and Elite Orthopaedics; consulting fees from Arthrex, Heron Therapeutics, Pacira, and Schwartz Biomedical; and
speaking fees from Arthrex. J.M. has received educational support from Elite Orthopaedics, consulting fees from Wright Medical, and speaking fees from
Arthrex and Wright Medical. M.V.S. has received educational support from Elite Orthopaedics, consulting fees from Arthrex and Flexion Therapeutics, and
speaking fees from Arthrex. R.W.W. has received royalties from Responsive Arthroscopy. R.H.B. has received educational support from Arthrex and Elite
Orthopaedics; consulting fees from Arthrex, ISTO Technologies, and Sanofi-Aventis; and speaking fees from Smith & Nephew. AOSSM checks author
disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or
responsibility relating thereto.
Ethical approval for this study was obtained from Washington University in St Louis (No. 201610143).

The Orthopaedic Journal of Sports Medicine

or wound dehiscence that did not require a surgical intervention or sural nerve disturbance (after either OP or NOP
treatment). Minor complications were defined as skin adhesion at the rupture site (after either OP or NOP treatment)
and noncosmetic scarring. Each of these 3 terminal events
as well as the other 2 events (well-being and reruptures)
was associated with 3 key variables in the analytical model:
 Probability (P; unitless): the probability of the occurrence of each of the terminal events after either OP or
NOP treatment
 Utility (U; unitless; range, 0-10): subjective outcome
measurement from the patients’ perspective
 Direct cost (C; US$): cost of each treatment arm from the
payers’ perspective
The detailed methods can be found in the Appendix.

Probability Data Acquisition
Probabilities (P) were populated from a level 1 systematic
review comparing primary open repair versus nonoperative
treatment for acute Achilles tendon ruptures. 28
The reported pooled rate of reruptures was assigned as
POP-rerupavg and PNOP-rerupavg to represent the average probability for the terminal node of reruptures in the OP and
NOP arms, respectively. The range of rerupture probabilities for each arm was represented by POP-rerup min and
POP-rerupmax as well as PNOP-rerupmin and PNOP-rerupmax as the
minimal and maximal probabilities for the OP and NOP
arms, respectively. These were determined by the minimal
and maximal rates among the 7 individual publications4,13,14,16,17,21,29 assessed in the systematic review.
The pooled rates as well as the minimal and maximal
rates of all the complications reported in the systematic
review28 were categorized under the 3 terminal nodes of
major complications, moderate complications, and minor
complications and were then summed to represent the
average and range of probabilities for each arm. The
remaining probability values outside of the rerupture and
complication rates were then assigned to the terminal node
of well-being of each treatment arm.

Outcome Utility Data Acquisition
The outcome utility (U) was represented as a unitless, continuous visual analog scale score from 0 to 10, with 0 being
the worst and 10 being the best possible subjective outcome.
The utility value for each of the 5 terminal events was
assigned as previously described in a study assessing
expected values for primary open repair versus nonoperative treatment.11 In short, a group of patients were asked to
complete a questionnaire that simulates the life scenarios
of the 5 terminal events for the OP and NOP treatment
arms. The average and range of utility values were then
determined by the mean value (and the span of 1 standard
deviation above and below such a value) reported in the
study.
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Cost Data Acquisition
Cost data (C) were obtained from the billing department of
a major tertiary care university medical center. The data
were pooled from the practices of 8 fellowship-trained
sports medicine and foot and ankle orthopaedic surgeons
over 2 years. The present study utilized the direct costs
from the payers’ perspective.
The cost of the OP treatment arm was the sum of payments for surgeon’s fees, hospital fees, anesthesiologist’s
fees, physical therapy, and outpatient clinic visits outside
of the 90-day global period as well as associated medical
devices. The cost of the NOP treatment arm was the sum of
payments for physical therapy and outpatient clinic visits as
well as associated medical devices. The cost for 1 outpatient
clinic visit was on par with that for 1 outpatient physical
therapy visit. The average costs for OP and NOP treatment
were represented by COPavg and CNOPavg, respectively.
Both the OP and NOP arms were assumed to undergo
accelerated rehabilitation protocols, as previously
described.29 The total numbers of outpatient physical
therapy and clinic visits were similar between the
2 arms.

Foldback Analysis for Expected Utility Values
A foldback analysis was performed to determine the ultimate
utility values for the OP and NOP treatment arms. For either
treatment arm, the contribution of each of the 5 terminal
events to the utility values was determined by the product
of U and P and was subsequently summed to reach the ultimate utility value for OP (UOPSUM) and NOP (UNOPSUM):
U OP SUM;avg ¼

event
X#5

OP;i
Uavg
 POP;i
avg

i¼event #1

U NOP SUM;avg ¼

event
X#5

NOP;i
Uavg
 PNOP;i
avg

i¼event #1

Cost-Utility Analysis
The average cost-utility ratio (CUR) was determined by normalizing the ultimate cost to the ultimate utility value, designated as CUROPavg and CURNOPavg, respectively, for the
OP and NOP arms to reflect the cost to gain 1 unit of utility:
CUROP avg ¼

COP
avg
OP
USUM;avg

CURNOP avg ¼

CNOP
avg
NOP
USUM;avg

Multiway Sensitivity Analyses
for Boundary Conditions
The possible range of utility values, probabilities of events,
and direct costs was included in the analytical model to
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TABLE 1
Probability and Outcome Utility Data for the 5 Major Eventsa
Probability, %

Well-being
OP
NOP
Reruptures
OP
NOP
Major complications
OP
NOP
Moderate complications
OP
NOP
Minor complications
OP
NOP

Outcome Utility

Average

Minimum

Maximum

Average

Minimum

Maximum

65.10
79.56

(Maximum)
95.10
95.50

(Minimum)
14.66
31.22

7.9
7.0

6.0
5.0

9.8
9.0

3.60
8.80

1.70
4.50

10.00
20.80

2.6
2.6

0.4
0.4

4.8
4.8

9.44
10.24

0.00
0.00

9.44
10.24

1.0
1.0

0.0
0.0

2.6
2.6

8.76
0.78

0.00
0.00

45.45
34.14

3.5
3.5

1.4
1.4

5.6
5.6

13.10
0.62

3.20
0.00

20.45
3.60

4.7
4.7

2.5
2.5

6.9
6.9

a

NOP, nonoperative; OP, operative.

account for the variability of such data. The highest possible CUR was determined by implementing the highest possible ultimate utility value and lowest possible cost, and
vice versa. The highest possible ultimate utility value was
computed by maximizing the probability of well-being, minimizing the probabilities of the other 4 events, and implementing the maximal utility value for each event. The
range of CURs for the OP and NOP arms was determined
accordingly.

Multiway Sensitivity Analyses
for Marginal Cost per Utility
The marginal cost per utility indicated the extra cost
that the payers needed to pay for OP treatment as
opposed to NOP treatment for 1 unit of utility, defined
as “marginal CUR”: DCUR ¼ CUROP  CURNOP. The
sensitivity analyses assessed the effect of the (1) marginal utility of well-being and (2) marginal rate of reruptures on DCUR.
The marginal utility was defined as the assumptive
gap of (UOP-Well  UNOP-Well) in a spectrum of 0 to 9.8,
respectively, corresponding to UOP-Wellavg, UOP-Wellmin,
and UOP-Wellmax. Such an analysis evaluated the assumptive scenario when OP treatment resulted in better than
average outcomes for higher demanding patients (higher
marginal utility) or else equal outcomes as compared
with NOP treatment for lower demanding patients
(marginal utility ¼ 0).
The marginal rate of reruptures was defined as the
assumptive gap of (PNOP-rerup  POP-rerup) in a spectrum of
0% to 20%, respectively, corresponding to PNOP-rerupavg,
PNOP-rerupmin, and PNOP-rerupmax. Such an analysis evaluated
the assumptive scenario when NOP treatment resulted in
higher than average or equal rerupture rates as compared
with OP treatment (marginal rerupture rate ¼ 0).

RESULTS
Acquired Data for Probability,
Outcome Utility, and Cost
The pooled average probabilities for reruptures were
3.6% and 8.8%, respectively, for the OP and NOP treatment arms. The average probabilities for the OP versus
NOP arms of major, moderate, and minor complications
were 9.4% versus 10.2%, 8.8% versus 0.8%, and 13.1%
versus 0.6%, respectively, resulting in average wellbeing probabilities of 65.1% versus 79.6%, respectively
(Table 1).
The average outcome utility of well-being for the OP
arm was 7.9, compared with 7.0 for the NOP arm. The
average and range of utilities for reruptures as well as
major, moderate, and minor complications were identical
for both treatment arms (Table 1). The average cost for OP
treatment (in US$) was $12,477 (range, $7594-$17,323)
versus $3100 (range, $1975-$4600) for NOP treatment
(Table 2).

Foldback and Cost-Utility Analyses
for Boundary Conditions
The foldback analysis revealed that the average ultimate
utility value for OP treatment was 6.3 versus 6.0 for NOP
treatment (Figure 1B). The average cost to gain 1 unit of
utility for the OP arm was approximately 3 times more than
that for the NOP arm (CUROPavg: $1995; CURNOPavg: $520).
Multiway sensitivity analyses for boundary conditions
showed crossover of the 2 treatment arms in which the
CUROPmin could be as low as $789 and the CURNOPmax
could be as high as $2079 (Figure 2). This indicated that
in certain scenarios, OP treatment can be more costeffective than NOP treatment.
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TABLE 2
Direct Cost of OP Versus NOP Treatmenta

OP (open repair)
Surgeon’s fee
Anesthesia fee
Hospital fee
Outpatient visitb
Associated medical devicec
Total
NOP
Outpatient visitb
Associated medical devicec
Total

Average

Minimum

Maximum

1468
1200
7209
2250
350
12,477

157
1200
4762
1125
350
7594

1783
1200
10,240
3750
350
17,323

2250
850
3100

1125
850
1975

3750
850
4600

a
Data are reported as US dollars. NOP, nonoperative; OP, operative.
b
Outpatient visits included clinic visits and physical therapy
sessions, which were estimated as an average of 22.5 visits (range,
15 to 30 visits) in total for both OP and NOP treatment, with the
average direct cost of $100 (range, $75-$125).
c
One boot and 1 set of crutches were included for both OP and
NOP treatment; an additional cost of short leg casting was applied
to NOP treatment.

Figure 2. Sensitivity analyses for boundary conditions for
operative (OP) versus nonoperative treatment, showing a
crossover in the range between the lowest and highest
possible cost-utility ratios (CURs). The numbers for each bar
represent the minimum (left), average (middle), and maximum
(right) values.

Multiway Sensitivity Analyses
for Marginal Cost per Utility
OP treatment cost an extra marginal CUR of $1475,
assuming the utility of well-being at the average values
of 7.9 and 7.0, respectively, for OP and NOP treatment.
The marginal CUR decreased as the marginal utility of
well-being increased. If such a utility value for OP treatment reached its maximum of 9.8 and that for NOP
treatment was 7.8 (marginal utility of well-being of
2.0), OP treatment cost an extra marginal CUR of
$1196 (Figure 3A).
OP treatment cost an extra marginal CUR of $1475,
assuming the probability of reruptures at the average
values of 3.6% and 8.8%, respectively, for OP and NOP
treatment. Sensitivity analyses, allowing for a greater
advantage to OP treatment with regard to rerupture rates,
decreased the marginal CUR. Even in the most favorable
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case, assuming a rerupture rate of 1.7% for OP treatment
and 21.7% for NOP treatment, however, the marginal CUR
was still $1388 (Figure 3B).

DISCUSSION
This pilot analysis revealed that operative treatment of
acute Achilles tendon ruptures had a higher incremental
cost per utility gained but also higher expected utility value
upon uneventful healing compared with nonoperative
treatment. On average, nonoperative treatment was more
cost-effective. Operative treatment became increasingly
cost-effective as the utility of well-being increased: for
example, with high-demand patients, such as athletes, or
those in physically demanding occupations who prefer the
highest possible functional outcome as early as possible.
Our study sought to provide novel information by incorporating actual cost data and updated outcome data into
the decision analysis model. While the basic structure of
the decision tree is similar to previous analyses,11 the probabilities of each outcome are expected to change over time
because of advancement in either treatment option. In
addition to the expected utility value alone, we integrated
direct cost data with sensitivity analyses, accounting for
potential heterogeneity among various patient populations
and the associated variables.
Primary open repair for acute Achilles tendon ruptures
may lead to favorable muscle strength in the first year after
surgery16 and fewer days to return to sports4 or work.19
These benefits may not be supported by other reports, as
some factors were measured differently in various sources
in the literature and are thus difficult to compare. Primary
open repair results in lower rates of reruptures, as reflected
by the pooled rerupture rate in the most recent Cochrane
review10 and by a level 1 systematic review.28 This may be
of critical concern for active patients who need high athletic
performance or a return to physically demanding occupations. Accordingly, operative treatment may reduce the
societal costs resulting from underperformance or loss of
work days.7
Nonoperative treatment is a cost-effective option and
could be especially suitable for the general population that
is not that active. Accelerated rehabilitation protocols
with early weightbearing and range of motion progression
can lead to decreased rerupture rates and similar objective
outcomes as operative treatment.16,21,29 The complications
associated with surgery become much less likely, as shown
in the pooled probabilities of moderate and minor complications in the present study. The probability of certain
major complications such as deep vein thrombosis remains
similar. The advantage of avoiding wound complications
may be offset in the near future by the advancement of
percutaneous repair techniques13 that are relatively novel
with emerging evidence to support promising midterm to
long-term outcomes. 5,12 A recent retrospective cohort
analysis demonstrated that percutaneous repair could be
more cost-effective than open repair,3 although more highlevel analyses of its effectiveness, cost, and utility are
needed.
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Figure 3. Sensitivity analyses for marginal cost-utility ratio (DCUR) of operative (OP) treatment as opposed to nonoperative
(Non-OP) treatment, implicating that OP treatment becomes increasingly cost-effective as its utility of well-being further exceeds
Non-OP treatment and its rerupture rate minimizes, which could be the scenario of treating certain young, active athletes. (A) DCUR
decreases as the utility of Non-OP treatment falls further behind OP treatment. (B) Decrease of DCUR as a function of increasing
rerupture probability of Non-OP treatment compared with OP treatment. Note that in most scenarios, Non-OP treatment is still
more cost-effective than OP treatment.
Sensitivity analyses reflecting lower rerupture rates
after primary surgical repair and higher rerupture rates
after nonoperative treatment narrowed the cost advantage for nonoperative treatment, but only slightly, as
shown in Figure 3B. Even under the scenario of a 20%
higher rerupture rate after nonoperative treatment compared with primary surgical repair, operative treatment
was still more expensive. However, while there is still variation regarding the rerupture rates of either treatment
option in the literature, the difference in rerupture rates
may be particularly important to certain patients depending on their lifestyle and expectations. In addition, the
costs of managing reruptures after initial treatment, be
it operative or nonoperative, can affect the overall costeffectiveness should these costs be included in future
analyses. Therefore, one should use caution in the interpretation of the results.
Surgical treatment for acute Achilles tendon ruptures
was found to be cost-effective in a prospective randomized
cohort study from Sweden.27 Using quality-adjusted life
years (QALYs) as the measure for the effectiveness of
treatment, the incremental cost-effectiveness ratio was
€45,885 per QALY, resulting in a 57% likelihood for surgical treatment to be cost-effective based on the €50,000
threshold of willingness to pay for 1 QALY. The rerupture
rate was 10% and 2.3% in their cohort, as opposed to 8.8%
and 3.6% in the present study, for nonoperative and operative treatment, respectively. Further, the costs and
health care infrastructure are distinct in different countries and may thus affect the cost-effectiveness of a variety
of treatment strategies.
Nonoperative treatment may be favorable for cost minimization from the payer’s perspective based on a claims
database in the US.20 The rates and associated costs of
managing complications did not significantly differ
between operative and nonoperative treatment. Based on

claims data, there appeared to be a trend toward treating
more of these Achilles tendon ruptures nonoperatively,
whereas younger patients were more likely treated with
surgery. These findings, although largely based on the
claims that the payers processed and focused on costs only,
resonated with our results, which were drawn from actual
cost data integrated with utility scores for costeffectiveness analyses.
Both QALY and utility values are common proxies to
quantify the effectiveness of treatment in costeffectiveness analyses. Because Achilles tendon ruptures
do not directly affect life expectancy, using QALY requires
the collection of subjective patient-reported outcomes,
which may be essentially on par with the acquisition of
utility values. The use of US$50,000 per QALY as the
willingness-to-pay threshold in the US can be traced back
to discussions in the 1970s on Medicare coverage for
patients with end-stage renal disease.8 Revising such a
threshold has been proposed to better reflect the current
health care system and the needs of modern society.15 Further justification is needed for its use in orthopaedic surgical procedures, particularly when patients’ willingness to
pay may widely vary based on their expected functional
outcome, which is paramount in the practice of sports medicine as well as foot and ankle surgery.
The scenario of chronic Achilles tendon ruptures was not
analyzed in the present study. These patients commonly
require more complex procedures such as soft tissue flaps,
tendon transfer or augmentation, or bridging materials. 18,24-26 The cost of such procedures is presumably
higher, and the outcome may be suboptimal compared with
the treatment of acute ruptures. The cost-effectiveness of
various treatment options in such a scenario may be difficult to assess because of a lack of sufficient case volume and
homogeneity in the published literature.
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Limitations
As a pilot investigation, the present study did have several
limitations. First, the data of costs, utilities, and probabilities were not acquired from exactly the same patient population. Second, we assessed only the direct costs from the
payers’ perspective and did not consider the societal costs
attributed to loss of work days and school days alike. The
outcome utility was populated from subjective patient reports
and did not include quantitative measurements such as
ankle push-off strength, which may affect athletic patients’
performance and thus place more emphasis on utility. Also,
the cost data were from a single academic institution.
In addition, our decision model did not account for the
full time horizon of each treatment arm, which may introduce additional costs resulting from further management of
reruptures and other complications. The potential costs
associated with complication management could be substantial, depending on the type of complication, the
expected outcome, and the underlying medical condition
of each patient. To date, there is insufficient high-level
evidence to support secondary analyses assessing the
cost-effectiveness of these complications. The results could
differ if such costs were incorporated in the future.
Despite these limitations, we optimized the validity of
this pilot study by incorporating data from the best available level 1 evidence as well as by performing multiway
sensitivity analyses.

Future Directions
This analysis can serve as a foundation for future investigation. The decision tree could further expand based on this
economic decision model, as more high-level evidence
becomes available regarding the cost and utility of complication management as well as percutaneous Achilles tendon repair procedures.

CONCLUSION
While practicing cost-effective medicine, optimizing outcomes as they relate to patients’ expectations for their work
and life should remain the surgeon’s top priority. In the
current study, nonoperative treatment was cost-effective
for the average patient population. This remained true
when the expected utility value decreased, as in patients
with lower physical demands, as well as when the surgical
complication rates increased, as in patients with medical
comorbidities. Primary open repair was less cost-effective
in the average scenario. However, its cost-effectiveness
increased when a higher utility value was expected, as in
young athletes or patients with higher physical demands.
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APPENDIX
Probability Data Acquisition
POP-wellavg and PNOP-wellavg, which represented the average probabilities of the well-being terminal node for the OP and NOP
arms, respectively, were determined by the following:


POP-well avg ¼ 100%  POP-rerup avg þ POP-maj avg þ POP-mod avg þ POP-mnr avg and


PNOP-well avg ¼ 100%  PNOP-rerup avg þ PNOP-maj avg þ PNOP-mod avg þ PNOP-mnr avg :
The minimal probabilities of well-being, POP-wellmin and PNOP-wellmin, were determined by the “maximal” probabilities of the
other 4 terminal nodes and vice versa:


POP-well min ¼ 100%  POP-rerup max þ POP-maj max þ POP-mod max þ POP-mnr max and


PNOP-well max ¼ 100%  PNOP-rerup min þ PNOP-maj min þ PNOP-mod min þ PNOP-mnr min :

Utility Data Acquisition
The average utility values for the OP and NOP arms were designated as UOP-wellavg, UOP-rerupavg, UOP-maavgj, UOP-modavg, and
UOP-mnravg, respectively, and UNOP-wellavg, UNOP-rerupavg, UNOP-majavg, UNOP-modavg, and UNOP-mnravg, respectively. The range of
such utility values was designated as UOP-wellmin, UOP-rerupmin, UOP-majmin, UOP-modmin, UOP-mnrmin, UOP-wellmax, UOP-rerupmax,
UOP-majmax, UOP-modmax, and UOP-mnrmax, respectively, and UNOP-wellmin, UNOP-rerupmin, UNOP-majmin, UNOP-modmin, UNOP-mnrmin,
UNOP-wellmax, UNOP-rerupmax, UNOP-majmax, UNOP-modmax, and UNOP-mnrmax, respectively, for the OP and NOP arms.
Cost Data Acquisition
The average and range of direct costs of OP and NOP treatment were represented by COPavg, COPmin, and COPmax as well as
CNOPavg, CNOPmin, and CNOPmax, respectively.
Multiway Sensitivity Analyses for Boundary Conditions
For example, the highest possible CUR for OP treatment was determined as follows:
CUROP
max ¼

COP
min
OP
USUM;
max

; where

OP
OP-well
-well þ U OP-rerup  POP-rerup þ U OP-maj  POP-maj þ U OP-mod  POP-mod þ U OP-mnr  POP-mnr
 POP
USUM;
max ¼ Umax
max
max
max
max
min
max
min
min
min

The range of CURs for the OP and NOP arms was then determined accordingly.

